Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics Corp is positioned for a positive growth trajectory, primarily driven by robust demand in its plasma and hospital segments, which are expected to yield high-single-digit to double-digit growth rates. The company's strategic emphasis on improving operating margins through favorable pricing, product mix, and cost management, along with the potential for accretive acquisitions, further enhances its financial outlook. Haemonetics is poised to shift a majority of its revenue toward high-growth MedTech markets, underscoring its strong brand reputation and expanding market presence.

Haemonetics Corp faces a negative outlook due to expected revenue growth slowing into the low-single digits, driven by mid-single digit growth in its plasma segment and high single-digit growth in its hospital segment, while its Interventional Technologies business is anticipated to decline further, negatively impacting operating margins. The company's Interventional Technologies sales experienced a 6.3% organic decline in the first half of FY26, which raises concerns about the sustainability of growth amidst increasing competition in the vascular closure device market. Furthermore, if organic growth continues to slow to mid-single digits or lower, Haemonetics shares may face significant risk of multiple compression, exacerbating the bearish sentiment surrounding the stock.